Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neutrophil-lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC).

Bioscience reports - 26 Jun 2020

Xiang Zi-Jun, Hu Tao, Wang Yun, Wang Hao, Xu Lin, Cui Ning

Abstract excerpt

Although the oncological outcomes in patients with pancreatic ductal adenocarcinoma (PDAC) have markedly improved over the past decade, the survival prediction is still challenging. The aim of this study was to investigate the prognostic value of neutrophil-lymphocyte ratio (NLR) and analyze the relationship of between the NLR and immune cells phenotypes in patients with PDAC. Sixty-seven consecutive patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Tumor-Associated, Carbohydrate
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunophenotyping

Share to Lymphocyte Count

Share to Neutrophils

Share to Pancreatic Neoplasms

Share to Progression-Free Survival

Share to T-Lymphocyte Subsets

Source

Open in PubMed Open full text

Identifiers

PMID: 32510138
DOI: 10.1042/BSR20201190
PMCID: PMC7300287

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neutrophil-lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC).PMID 32510138Read ↗

The Impact of Immune Microenvironment on the Prognosis of Pancreatic Ductal Adenocarcinoma Based on Multi-Omics Analysis.Semantic proximity Read ↗

Immune profiling and prognostic model of pancreatic cancer using quantitative pathology and single-cell RNA sequencingSemantic proximity Read ↗

Immune landscape and prognostic index for pancreatic cancer based on TCGA database and in vivo validationSemantic proximity Read ↗

Comparative Immune profiling in Pancreatic Ductal Adenocarcinoma Progression Among South African patientsSemantic proximity Read ↗

High expression of TLR2 influenced immune infiltration in pancreatic cancerSemantic proximity Read ↗

Prognostic value of inflammation-based indices in patients with resected hepatocellular carcinomaSemantic proximity Read ↗

Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Subtype-specific HERV-K102 envelope is a novel serum immunosuppressive biomarker and therapeutic target of cancerSemantic proximity Read ↗

Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma: an open-label, phase Ib/II study and investigation of potential biomarkersSemantic proximity Read ↗

Association of the CD4+ /CD8+ ratio with response to PD-1 inhibitor-based combination therapy and dermatologic toxicities in patients with advanced gastric and esophageal cancerSemantic proximity Read ↗

Characterization and predictive value of lymphocyte subsets in peripheral blood of patients with colorectal cancerSemantic proximity Read ↗

Myeloid-derived suppressor cells and their role in pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.